Welcome to our dedicated page for Altamira Therapeutics news (Ticker: CYTO), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics stock.
Overview of Altamira Therapeutics Ltd (CYTO)
Altamira Therapeutics Ltd, formerly known as Auris Medical, is a specialized biopharmaceutical company dedicated to developing innovative therapeutics that address significant unmet medical needs. With a robust emphasis on RNA therapeutics, nasal spray innovation, and intratympanic treatments, the company has strategically diversified its pipeline into three primary therapeutic areas. Trading on the Nasdaq Capital Market under the symbol CYTO, Altamira Therapeutics has established itself as a key player within the biotechnology and pharmaceutical industries.
Core Therapeutic Areas and Product Pipeline
The company’s research and development efforts are concentrated in three distinct areas:
- RNA Therapeutics for Extrahepatic Targets: Leveraging its proprietary oligophore™ and semaphore™ platforms, Altamira is actively engaged in the preclinical development of RNA therapies aimed at extrahepatic targets, showcasing its commitment to harnessing novel molecular mechanisms for therapeutic intervention.
- Nasal Spray Therapies: The company has advanced products in the nasal spray category, including formulations designed for protection against airborne viruses and allergens through a barrier-forming technology. Additionally, it is engaged in the clinical exploration of nasal sprays for the treatment of vertigo, evidencing its ability to diversify applications within a single product family.
- Intratympanic Treatments for Tinnitus and Hearing Loss: With therapies such as keyzilen® and sonsuvi® in advanced clinical stages, Altamira Therapeutics is pioneering targeted approaches for intratympanic delivery, addressing complex auditory disorders with precision and specialized delivery methods.
Research, Development, and Clinical Innovation
Altamira Therapeutics is firmly rooted in a research-intensive model driven by state-of-the-art technologies, and its R&D framework is designed to integrate academic insights and clinical expertise. The company emphasizes a rigorous, phased approach to clinical development, ensuring its therapeutic candidates are systematically validated through preclinical and clinical trials. This approach not only strengthens its product pipeline but also reinforces the company's commitment to safety, efficacy, and regulatory compliance.
Operational and Geographic Footprint
Founded in 2003, the company has evolved its operational core from its origins as Auris Medical, now headquartered in Hamilton, Bermuda, with major operational centers in Basel, Switzerland. This dual geographic presence enables Altamira Therapeutics to harness advanced research infrastructure, foster international collaborations, and maintain a dynamic pipeline of innovative therapeutics.
Competitive Position and Market Significance
Within a competitive biotechnology landscape, Altamira Therapeutics distinguishes itself not merely by its diversified therapeutic strategies but also by its deep scientific acumen and commitment to innovation. Its targeted approach in RNA therapeutics, coupled with the strategic development of both prophylactic and therapeutic nasal sprays and advanced intratympanic treatments, positions the company effectively among its peers. The integration of precise delivery systems and molecular targeting underscores a methodology that is both scientifically robust and clinically relevant.
Commitment to Innovation and Scientific Rigor
Altamira Therapeutics demonstrates a high level of expertise through its meticulous research processes and the use of advanced scientific platforms. The company’s development efforts are supported by comprehensive preclinical research and progressive clinical trials, which collectively form the backbone of its mission to address complex medical challenges. This commitment to innovation, combined with detailed process validation and regulatory alignment, underpins its authoritative position in the biotechnology sector.
Investor FAQ and Research Considerations
For investors and industry analysts, Altamira Therapeutics offers a transparent view into its business model, pipeline progression, and strategic market positioning. The company’s focus on high-need therapeutic areas, advanced delivery mechanisms, and a globally oriented operational footprint makes it a subject of interest for those keen on understanding the intersection of scientific innovation and clinical application in biotech.
Altamira Therapeutics announced its transition from NASDAQ to OTCQB marketplace following a delisting notice from the Nasdaq Hearings Panel on December 18, 2024. The delisting, effective December 20, 2024, results from the company's failure to maintain the required minimum bid price of $1.00 per share under Nasdaq's Rule 5550(a)(2).
The company will continue trading under the ticker symbol CYTOF on the OTCQB platform, ensuring uninterrupted market activity for shareholders with no action required. Altamira had previously received a delisting notification on September 30, 2024, and appealed to present its compliance plan, which was ultimately denied by the Panel.
Altamira Therapeutics (Nasdaq:CYTO) announced on October 4, 2024, that it received a letter from Nasdaq's Listing Qualifications Department on September 30, 2024. The letter stated that Altamira no longer complied with Rule 5550(a)(2) of Nasdaq's Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share. This non-compliance occurred because the bid price of Altamira's listed securities closed at less than $1.00 per share over 30 consecutive business days, from August 16, 2024, through September 27, 2024.
The company is not eligible for a cure period due to having effectuated one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. Altamira intends to appeal this determination to a hearing panel, which will result in a stay of any suspension or delisting action pending the hearing. However, there is no assurance that the Panel will grant Altamira's request for continued listing or any extension.
Altamira Therapeutics has announced an extended ISO 13485 certification for its quality management system, now including production activities for Bentrio nasal spray. This certification covers the entire process from design and development to production and distribution.
The extended certification is a significant milestone in Altamira's growth strategy for Bentrio, which involves collaboration with a strategic contract manufacturer and an expanding network of international distributors. Thomas Meyer, Chairman and CEO of Altamira Medica, emphasized the importance of this achievement in ensuring Bentrio's compliance with high quality standards and regulatory requirements.
This development supports Altamira's efforts to expand the reach of Bentrio in the market, reinforcing its commitment to quality and regulatory compliance in the medical device industry.
Altamira Therapeutics (Nasdaq:CYTO) reported its first half 2024 financial results, highlighting key developments in RNA delivery and business restructuring.
The company showcased progress in its RNA delivery platforms, OligoPhore and SemaPhore, with notable scientific publications demonstrating efficacy in cancer and inflammatory disease treatments. Altamira's R&D team moved to new facilities at Switzerland Innovation Park, enhancing their capabilities.
Financial results showed a net loss of $4.3 million, a 27% improvement from the previous year's $5.9 million. Operating loss from continuing operations was $3.9 million, up from $3.6 million in H1 2023, mainly due to increased R&D expenses. Cash used in operations decreased significantly to $3.2 million from $8.4 million in H1 2023.
Altamira expanded distribution territories for Bentrio®, its nasal spray, and continued strategic repositioning towards RNA delivery by divesting a 51% stake in Altamira Medica for $2.3 million. The company also raised $4.7 million through share issuances and a public offering.
Altamira Therapeutics (Nasdaq: CYTO), a company specializing in nanoparticle-based RNA delivery technology, has announced its upcoming First Half 2024 Financial Results and Business Update Call. The event is scheduled for Tuesday, September 24, 2024, at 8:30 am ET.
Key participants in the call will be Founder, Chairman, and CEO Thomas Meyer, along with COO Covadonga Pañeda. They will present prepared remarks followed by a Q&A session open to investors and analysts.
Interested parties can access the webcast through the provided URL. Additionally, a registration link is available for those who wish to join the call via phone. Multiple options for joining are offered, including dial-in with a unique PIN and a 'Call Me' feature. A replay of the call will be accessible through the webcast link after the live event concludes.
Altamira Therapeutics announced the closing of its public offering, raising approximately $4.0 million upfront with potential additional gross proceeds of $8.0 million upon full exercise of milestone-linked warrants. The offering included 5,555,556 common shares (or pre-funded warrants) and accompanying Series A-1 and A-2 common warrants at a combined price of $0.72 per share. The Series A-1 warrants are exercisable immediately and expire on the earlier of 18 months from issuance or 60 days post-positive biodistribution data announcement. Series A-2 warrants also are immediately exercisable and expire on the earlier of five years from issuance or six months post-agreement announcement covering specific territories. H.C. Wainwright & Co. acted as the exclusive placement agent. Net proceeds will be used for working capital and general corporate purposes. Additionally, existing warrants for 555,556 common shares were amended to reduce the exercise price to $0.72 per share.
Altamira Therapeutics (Nasdaq: CYTO) has announced the pricing of a public offering to raise up to $12 million. The offering includes 5,555,556 common shares (or pre-funded warrants) with accompanying Series A-1 and A-2 common warrants, priced at $0.72 per share. The initial gross proceeds are expected to be $4 million, with potential additional proceeds of $8 million if all warrants are exercised. The funds will be used for working capital and general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent. The offering is expected to close around September 19, 2024. Additionally, certain existing warrants will be amended to reduce the exercise price from $9.00 to $0.72 per common share.
Altamira Therapeutics (Nasdaq: CYTO) announced the expansion of its Bentrio® nasal spray license and distribution agreement with Nuance Pharma. The extended agreement now includes seven additional countries in East and South East Asia, covering a population of over 630 million. Nuance has successfully launched Bentrio in Hong Kong and filed for marketing authorization in Mainland China. The expanded territory includes Singapore, Malaysia, Thailand, Philippines, Indonesia, Vietnam, and Taiwan, in addition to the original markets of China, Hong Kong, Macau, and South Korea.
Thomas Meyer, Altamira Medica's CEO, expressed satisfaction with the collaboration, while Mark G. Lotter, Nuance Pharma's CEO, highlighted Bentrio's unique features and positive market reception. The partnership aims to provide relief to the growing number of allergic rhinitis patients in the region.
Altamira Therapeutics (Nasdaq: CYTO), a company focused on RNA delivery technology for targets beyond the liver, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place both virtually and in person from September 9-11, 2024, at the Lotte New York Palace Hotel in New York City.
Thomas Meyer, the founder, Chairman, and CEO of Altamira, will deliver an on-demand presentation starting at 7:00am ET on September 09, 2024. Registered attendees will have the opportunity to submit questions for the company after the presentation becomes available. Investors interested in scheduling a one-on-one meeting with Mr. Meyer are encouraged to email meetings@hcwco.com.
Altamira Therapeutics (Nasdaq:CYTO) has announced an extension of its exclusive distribution agreement for Bentrio with Pharma Nordic AS to include Sweden and Denmark, in addition to Norway. This follows the successful launch of Bentrio in Norway earlier in 2024. Pharma Nordic plans to introduce the nasal spray for prevention and treatment of allergic rhinitis in these two additional Scandinavian countries next year.
The CEO of Altamira Medica, Thomas Meyer, expressed satisfaction with Pharma Nordic's market launch activities in Norway. Bent Andreassen, CEO of Pharma Nordic, noted favorable responses from the medical community and patients, highlighting Bentrio's drug-free and preservative-free formulation as well as its efficacy and tolerability data.
FAQ
What is the current stock price of Altamira Therapeutics (CYTO)?
What is the market cap of Altamira Therapeutics (CYTO)?
What is the primary focus of Altamira Therapeutics?
How does Altamira Therapeutics generate its revenue?
What therapeutic areas does Altamira Therapeutics target?
Where is Altamira Therapeutics headquartered?
What technologies does the company employ in its drug development?
How does Altamira Therapeutics differentiate itself in the biotech industry?
What stage of development are its therapies currently in?
How does Altamira Therapeutics address unmet medical needs?
